Dyspepsia Articles
Dyspepsia is a common term used for the abdominal symptoms of a heterogeneous population. This review focuses on Functional
dyspepsia (FD). FD and its subgroups, postprandial distress
syndrome (PDS) and epigastric pain
syndrome (EPS) were defined in the Rome III criteria of 2006. FD is a very common condition with a high prevalence worldwide which adversely affects patients ' quality of life. For the last two decades the pathophysiology of FD has been under study. Multiple mechanisms are likely to be involved, such as abnormal gastric emptying, visceral hypersensitivity, impaired stomach accommodation and central nervous system factors. There are several tests available to assess different
physiological functions that may be involved in FD pathogenesis, some of which may be used in clinical practice, helping to explain the symptoms that underline the concerns of patients. However, experience of using prokinetics, tricyclic antidepressants, selective serotonin-reuptake inhibitors (SSRIs), proton-pump inhibitors (PPIs) and other alternative therapies have been acquired, the possibilities of pharmacological therapy for FD are still restricted. The various combinations of alterations in gastrointestinal physiological and central nervous system functions result in FD being very heterogeneous in nature.
High Impact List of Articles
-
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
CONSORT 2010: progress and challenges
Larissa Shamseer, David Moher
Editorial: Clinical Investigation
-
CONSORT 2010: progress and challenges
Larissa Shamseer, David Moher
Editorial: Clinical Investigation
-
CONSORT 2010: progress and challenges
Larissa Shamseer, David Moher
Editorial: Clinical Investigation
-
CONSORT 2010: progress and challenges
Larissa Shamseer, David Moher
Editorial: Clinical Investigation
-
CONSORT 2010: progress and challenges
Larissa Shamseer, David Moher
Editorial: Clinical Investigation
-
CONSORT 2010: progress and challenges
Larissa Shamseer, David Moher
Editorial: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Massimo Breccia, Giuliana Alimena
Review Article: Clinical Investigation
-
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Massimo Breccia, Giuliana Alimena
Review Article: Clinical Investigation
-
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Massimo Breccia, Giuliana Alimena
Review Article: Clinical Investigation
-
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Massimo Breccia, Giuliana Alimena
Review Article: Clinical Investigation
-
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Massimo Breccia, Giuliana Alimena
Review Article: Clinical Investigation
-
Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence
Massimo Breccia, Giuliana Alimena
Review Article: Clinical Investigation
Relevant Topics in Medical